Posts
NovaRed’s AI advisor is not just a mining add-on
I looked up Dr. Olamide Oladeji’s Stanford Knight-Hennessy profile after NovaRed named him Strategic Advisor for Robotics and AI. This is not a random “AI” title being stapled onto a mining story. Stanford lists him as a Knight-Hennessy Scholar and Stanford PhD in Management Science and Engineering, with dual MIT …
Orion Energy Systems (OESX)
TLDR: OESX, a pennystock , might rise insanely if their AI product line gains more traction. Not the 50 million mcap the tape makes it look like. Orion is a steady, medium-sized Wisconsin lighting and EV company with $86M in revenue and last year they quietly pulled off the hard …
$CXAI DD: The Market Is Waiting for Proof
It's been a frustrating couple of weeks, CXAI believers. Many of us expected more (I know I have) after the EngineRoom acquisition, the CXAI 2.0 launch, and continued momentum in enterprise AI. Instead, the stock has drifted lower, volume has cooled, and sentiment has become mixed. So the question is: …
$AIMD - Interview with Zacks SCR analyst
This interview covers how Ainos is building a Smell AI platform that transforms scent signals into machine-readable Smell IDs, and why company believes scent could become an important new data for AI. It also discuss AIMD's commercial focus in semiconductor manufacturing, robotics, and healthcare, and how real-world deployment helps build …
MASK, i bet it's gonna fly soon.
Been observing this stock for a while. i bet it is gonna fly before july ends. I've observe how the stock has been accumulated. And there are not much sellers left. It is currently flattening quietly and going sideways. Without sellers, there are only 2 ways the stock can go …
The Lounge
Talk about your daily plays, ideas and strategies that do not warrant an actual post. This is the place to request buy/sell advice from the community. Remember to keep it civil. Trade responsibly.
Stay away form EMI dangerous economic outlook is coming
GANX Therapeutics - Update
Good News here: # Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease BETHESDA, Md., June 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the …
Red days separate watchlists from wishlists
Red days in mining are where I actually build the watchlist. Not every dip is worth buying. Some names are weak for a reason. But when the whole group pulls back, it gives a cleaner look at which stocks are sitting near support, which ones still have volume, and which …
Microvision ( MVIS) Is the market underestimating Lidar 2.0?
I've been watching for 1.5 years and almost didn't even trade them. What changed my mind about investing in them was their change in expanding their focus from only Providing Lidar solutions to the Automotive industry to both the Industrial and Defense industries. which was about a year ago! This …